Prognosis of stage III colorectal carcinomas with FOLFOX adjuvant chemotherapy can be predicted by molecular subtype.
Prognosis of stage III colorectal carcinomas with FOLFOX adjuvant chemotherapy can be predicted by molecular subtype.
复制标题
FOLFOX辅助化疗的III期结直肠癌的预后可以通过分子亚型进行预测。
DOI：
10.18632/oncotarget.17023
复制
发表时间：
2017-06-13
期刊：
影响因子：
--
通讯作者：
Kim H
中科院分区：
文献类型：
--
作者：
Kwon Y;Park M;Jang M;Yun S;Kim WK;Kim S;Paik S;Lee HJ;Hong S;Kim TI;Min B;Kim H
个体化辅助化疗在晚期结直肠癌（CRC）患者中很重要，并且在辅助化疗后识别预测III期CRC良好预后的分子亚型的能力可能非常有益。我们对来自接受FOLFOX辅助化疗的III期CRC患者的101份新鲜冷冻原发样本和35份匹配的非肿瘤粘膜组织进行了基于微阵列的基因表达分析。使用非负矩阵因子分解将CRC样本分为四种分子亚型，为了比较，我们还使用建议的共有分子亚型（CMS）对CRC样本进行分组。在101例病例中，80例被归类为CMS组，这表明CMS分类与我们的四种分子亚型之间的相关性为79%。我们发现，我们的两个亚型显示出显着更高的无病生存期和总生存率比其他。特别是第2组，没有出现疾病复发或死亡，其特征是高微卫星不稳定性（MSI-H，6/21）、丰富的粘蛋白产生（12/21）和右侧位置（12/21）;该组与CMS 1（微卫星不稳定性免疫型）强相关。我们进一步鉴定了每组的分子特征，并从每组中选择了10个潜在的生物标志物基因。当这些与先前报道的分子分类器基因进行比较时，我们发现40个选择的基因中有31个与先前报道的基因相匹配。我们的研究结果表明，分子分类可以揭示与临床病理特征相关的特定分子亚型，并对FOLFOX辅助化疗的III期CRC的预后具有预测价值。
Individualizing adjuvant chemotherapy is important in patients with advanced colorectal cancers (CRCs), and the ability to identify molecular subtypes predictive of good prognosis for stage III CRCs after adjuvant chemotherapy could be highly beneficial. We performed microarray-based gene expression analysis on 101 fresh-frozen primary samples from patients with stage III CRCs treated with FOLFOX adjuvant chemotherapy and 35 matched non-neoplastic mucosal tissues. CRC samples were classified into four molecular subtypes using nonnegative matrix factorization, and for comparison, we also grouped CRC samples using the proposed consensus molecular subtypes (CMSs). Of the 101 cases, 80 were classified into a CMS group, which shows a 79% correlation between the CMS classification and our four molecular subtypes. We found that two of our subtypes showed significantly higher disease-free survival and overall survival than the others. Group 2, in particular, which showed no disease recurrence or death, was characterized by high microsatellite instability (MSI-H, 6/21), abundant mucin production (12/21), and right-sided location (12/21); this group strongly correlated with CMS1 (microsatellite instability immune type). We further identified the molecular characteristics of each group and selected 10 potential biomarker genes from each. When these were compared to the previously reported molecular classifier genes, we found that 31 out of 40 selected genes were matched with those previously reported. Our findings indicate that molecular classification can reveal specific molecular subtypes correlating with clinicopathologic features of CRCs and can have predictive value for the prognosis for stage III CRCs with FOLFOX adjuvant chemotherapy.
登录
查看更多内容
WGCNA：用于加权相关网络分析的 R 包。
影响因子：
3
作者：
Langfelder P;Horvath S
通讯作者：
Horvath S
抗原加工机械和HLA I类缺陷与宫颈癌中临床病理结果的关联。
影响因子：
5.8
作者：
Mehta, Akash M.;Jordanova, Ekaterina S.;Kenter, Gemma G.;Ferrone, Soldano;Fleuren, Gert-Jan
通讯作者：
Fleuren, Gert-Jan
DOI：
10.1073/pnas.0508647102
发表时间：
2005-11-29
影响因子：
11.1
作者：
Hwang, D;Rust, AG;Bolouri, H
通讯作者：
Bolouri, H
影响因子：
5.8
作者：
Kim, Hyunsoo;Park, Haesun
通讯作者：
Park, Haesun
影响因子：
64.8
作者：
Jiang, Le;Kon, Ning;Li, Tongyuan;Wang, Shang-Jui;Su, Tao;Hibshoosh, Hanina;Baer, Richard;Gu, Wei
通讯作者：
Gu, Wei